Cited by 1,509Chemotherapy-induced cardiotoxicity and mitigationBioactive Compounds and Antitumor AgentsCancer therapeutics and mechanisms

The DOI matches its Crossref record.

Doxorubicin: The Good, the Bad and the Ugly Effect

Carvalho, Cristina, Santos, Renato, Cardoso, Susana, Correia, Sonia, Oliveira, Paulo, Santos, Maria, Moreira, Paula·2009·Current Medicinal Chemistry

DOI 10.2174/092986709788803312

Open this paper in CoChat — free account

Abstract

The anthracycline doxorubicin (DOX) is widely used in chemotherapy due to its efficacy in fighting a wide range of cancers such as carcinomas, sarcomas and hematological cancers. Despite extensive clinical utilization, the mechanisms of action of DOX remain under intense debate. A growing body of evidence supports the view that this drug can be a double-edge sword. Indeed, injury to nontargeted tissues often complicates cancer treatment by limiting therapeutic dosages of DOX and diminishing the quality of patients' life during and after DOX treatment. The literature shows that the heart is a preferential target of DOX toxicity. However, this anticancer drug also affects other organs like the brain, kidney and liver. This review is mainly devoted to discuss the mechanisms underlying not only DOX beneficial effects but also its toxic outcomes. Additionally, clinical studies focusing the therapeutic efficacy and side effects of DOX treatment will be discussed. Finally, some potential strategies to attenuate DOX-induced toxicity will be debated.

Integrity signals

Registry

Crossref · 10.2174/092986709788803312

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 201–300 of 1,000

Protective effects of L-theanine against doxorubicin-induced nephrotoxicity in rats
Altınkaynak, Y., Kural, B. V., Akçan, B., Bodur, A., Özer, S., Yuluğ, E., Munğan, S., Kaya, C., & Örem, A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.171 · Cited by 62
Preparation and physicochemical properties of cisplatin and doxorubicin encapsulated by niosome alginate nanocarrier for cancer therapy
Sharafshadeh, M. S., Tafvizi, F., Khodarahmi, P., & Ehtesham, S. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123686 · Cited by 61
MicroRNAs as potential biomarkers for doxorubicin-induced cardiotoxicity
Holmgren, G., Synnergren, J., Andersson, C. X., Lindahl, A. H., & Sartipy, P. (2016) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.03.009 · Cited by 63
“Treatment with anthracycline-based chemotherapy is however, associated with severe cardiotoxicity, often resulting in early discontinuation (Carvalho et al., 2009; Ferreira et al., 2008; Minotti et al., 2004; Zhang et al., 2009).”
Background
Alpha lipoic acid prevents doxorubicin-induced nephrotoxicity by mitigation of oxidative stress, inflammation, and apoptosis in rats
El‐Sayed, E. M., Mansour, A. M., & El-Sawy, W. S. M. (2017) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21940 · Cited by 61
C-phycocyanin Mitigates Cognitive Impairment in Doxorubicin-Induced Chemobrain: Impact on Neuroinflammation, Oxidative Stress, and Brain Mitochondrial and Synaptic Alterations
Wang, C., Zhao, Y., Wang, L., Pan, S., Liu, Y., Li, S., & Wang, D. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03164-2 · Cited by 61
Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles
Bagheri, E., Alibolandi, M., Abnous, K., et al. (2021) · Journal of Materials Chemistry B · doi:10.1039/d0tb01960g · Cited by 60
Nerolidol Attenuates Oxidative Stress, Inflammation, and Apoptosis by Modulating Nrf2/MAPK Signaling Pathways in Doxorubicin-Induced Acute Cardiotoxicity in Rats
Arunachalam, S., Meeran, M. F. N., Azimullah, S., Sharma, C., Goyal, S. N., & Ojha, S. K. (2021) · Antioxidants · doi:10.3390/antiox10060984 · Cited by 66
Effects of Lignin-Based Hollow Nanoparticle Structure on the Loading and Release Behavior of Doxorubicin
Zhou, Y., Han, Y., Li, G., & Chu, F. (2019) · Materials · doi:10.3390/ma12101694 · Cited by 63
Caffeic acid phenethyl ester counteracts doxorubicin-induced chemobrain in Sprague-Dawley rats: Emphasis on the modulation of oxidative stress and neuroinflammation
Ali, M. A., Menze, E. T., Tadros, M., & Tolba, M. F. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108334 · Cited by 61
Synthesis and Characterization of Biodegradable and Thermosensitive Polymeric Micelles with Covalently Bound Doxorubicin-Glucuronide Prodrug via Click Chemistry
Talelli, M., Morita, K., Rijcken, C. J. F., Aben, R. W. M., Lammers, T., Scheeren, H. W., van Nostrum, C. F., Storm, G., & Hennink, W. E. (2011) · Bioconjugate Chemistry · doi:10.1021/bc2003499 · Cited by 61
Doxorubicin–Gelatin/Fe3O4–Alginate Dual-Layer Magnetic Nanoparticles as Targeted Anticancer Drug Delivery Vehicles
Huang, C.-H., Chuang, T.-J., Ke, C., & Yao, C. (2020) · Polymers · doi:10.3390/polym12081747 · Cited by 60
Curation of over 10 000 transcriptomic studies to enable data reuse
Lim, N., Tesar, S., Belmadani, M., Poirier‐Morency, G., Mancarci, B. O., Sicherman, J., Jacobson, M., Leong, J., Tan, P., & Pavlidis, P. (2021) · Database · doi:10.1093/database/baab006 · Cited by 56
“Separately, we found that ‘doxorubicin’ (CHEBI_28748, N=29), a widely used chemotherapeutic was not included under the term ‘antineoplastic agent’ (59), indicating incompleteness of relationship annotation in ChEBI, a common problem in ontologies in general (60).”
Background
GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy
Hu, D., Mezghrani, O., Zhang, L., Chen, Y., Ke, X., & Ci, T. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s113469 · Cited by 60
“Introduction Doxorubicin (DOX), an anthracycline antibiotic possessing broad-spectrum antineoplastic activity, is one of the most active anticancer agents in the treatment of breast cancer.(1) However, the clinical utility of DOX is hampered by cumulative, doselimiting cardiotoxicity, myelosuppression, and the develop…”
Background
A super-stable homogeneous Lipiodol-hydrophilic chemodrug formulation for treatment of hepatocellular carcinoma
He, P., Ren, E., Chen, B., et al. (2022) · Theranostics · doi:10.7150/thno.68456 · Cited by 58
“The toxicity of DOX mainly includes cardiac toxicity, renal toxicity and damage to liver function [30,31].”
Background
Synergism of ellagic acid in combination with radiotherapy and chemotherapy for cancer treatment
Xue, P., Zhang, G., Zhang, J., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.153998 · Cited by 58
Exercise as a beneficial adjunct therapy during Doxorubicin treatment—Role of mitochondria in cardioprotection
Ascensão, A. A. M. R., Oliveira, P. J., & Magalhães, J. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.05.060 · Cited by 60
“The antitumor activity of DOX is attributed to its ability to intercalate into both nuclear and mitochondrial DNA double helix and/or to covalently bind to proteins involved in DNA replication and transcription, leading ultimately to cellular death through the inhibition of DNA, RNA and protein synthesis [2–4].”
BackgroundSelf-citation
Recent Advances in Hydrogen Peroxide Responsive Organoborons for Biological and Biomedical Applications
Saxon, E., & Peng, X. (2021) · ChemBioChem · doi:10.1002/cbic.202100366 · Cited by 60
Hydrophobic ion pairing as a strategy to improve drug encapsulation into lipid nanocarriers for the cancer treatment
Oliveira, M. S., Goulart, G. A. C., Ferreira, L. A. M., & Carneiro, G. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1266329 · Cited by 57
TRP Channels in the Focus of Trigeminal Nociceptor Sensitization Contributing to Primary Headaches
Dux, M., Rosta, J., & Meßlinger, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010342 · Cited by 56
“A potent anthracycline-type antitumor agent, adriamycin, is used in the treatment of various malignancies [162].”
Background
Synthesis and characterization of a novel, pH-responsive sustained release nanocarrier using polyethylene glycol, graphene oxide, and natural silk fibroin protein by a green nano emulsification method to enhance cancer treatment
Jeshvaghani, P. A., Pourmadadi, M., Yazdian, F. A., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.226 · Cited by 56
Recent Advances in Stimuli-Responsive Doxorubicin Delivery Systems for Liver Cancer Therapy
Radu, E. R., Semenescu, A., & Voicu, Ș. I. (2022) · Polymers · doi:10.3390/polym14235249 · Cited by 61
“It was reported that the antitumor activity of doxorubicin is due to its ability to intercalate into the DNA helix and/or bind covalently to proteins involved in DNA replication and transcription, resulting in an inhibitory ef‐ fect on DNA, RNA, and proteins’ synthesis, leading to cell death [19,20].”
Background
Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity
Bamodu, O. A., Huang, W.-C., Tzeng, D. T. W., Wu, A. T. H., Wang, L. S., Yeh, C., & Chao, T.-Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.006 · Cited by 58
ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors
Deng, J., Shao, J., Markowitz, J. S., & An, G. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1389-0 · Cited by 58
“mucositis, and alopecia, respectively [1–4].”
Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity
Wu, J., Guo, W., Lin, S.-Z., Wang, Z.-J., Kan, J.-T., Chen, S.-Y., & Zhu, Y. Z. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.209 · Cited by 56
“Doxorubicin (Dox), an anthracycline derivative, is effective for a broad range of soft and solid human malignancies.(13)”
Background
Folic acid and trastuzumab conjugated redox responsive random multiblock copolymeric nanocarriers for breast cancer therapy: In-vitro and in-vivo studies
Kumar, A., Lale, S. V., Alex, M. R. A., Choudhary, V., & Koul, V. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.10.044 · Cited by 59
Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer
Katsuta, E., Yan, L., Nagahashi, M., Raza, A., Sturgill, J., Lyon, D., Rashid, O. M., Hait, N. C., & Takabe, K. (2017) · Journal of Surgical Research · doi:10.1016/j.jss.2017.05.101 · Cited by 56
“It is regarded as one of the most potent chemotherapeutic drugs (1, 2) and its response rate for metastatic lesions is approximately 25–40% (3).”
Manufacturing drug co-loaded liposomal formulations targeting breast cancer: Influence of preparative method on liposomes characteristics and in vitro toxicity
Gkionis, L., Campbell, R. A., Aojula, H. S., et al. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119926 · Cited by 56
Biomimetic nanotherapy: core–shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma
Zhao, Q., Jiang, D., Sun, X., Mo, Q., Chen, S., Chen, W., Gui, R., & Ma, X. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00922-4 · Cited by 56
“cardiotoxicity due to short half-life and non-specific distribution, limiting its clinical application [4].”
Background
Organ-On-A-Chip Technology: An In-depth Review of Recent Advancements and Future of Whole Body-on-chip
Driver, R., & Mishra, S. (2022) · BioChip Journal · doi:10.1007/s13206-022-00087-8 · Cited by 61
Doxorubicin-Loaded Nanobubbles Combined with Extracorporeal Shock Waves: Basis for a New Drug Delivery Tool in Anaplastic Thyroid Cancer
Marano, F., Argenziano, M., Frairia, R., Adamini, A., Bosco, O., Rinella, L., Fortunati, N., Cavalli, R., & Catalano, M. G. (2016) · Thyroid · doi:10.1089/thy.2015.0342 · Cited by 54
“Doxorubicin is the only chemotherapeutical drug approved by the FDA for ATC treatment in monotherapy (12), but it has a poor clinical response (13,14), and extremely severe side effects (15,16,43).”
Nuclear Targeting with an Auger Electron Emitter Potentiates the Action of a Widely Used Antineoplastic Drug
Imstepf, S., Pierroz, V., Raposinho, P., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00466 · Cited by 55
Enhancing Doxorubicin Delivery toward Tumor by Hydroxyethyl Starch-g-Polylactide Partner Nanocarriers
Yu, C., Zhou, Q., Xiao, F., Li, Y., Hu, H., Wan, Y., Li, Z., & Yang, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b00048 · Cited by 55
Doxorubicin Anticancer Drug Monitoring by ds-DNA-Based Electrochemical Biosensor in Clinical Samples
Moghaddam, F. H., Taher, M. A., & Karimi‐Maleh, H. (2021) · Micromachines · doi:10.3390/mi12070808 · Cited by 54
The role of iron in doxorubicin-induced cardiotoxicity: recent advances and implication for drug delivery
Qin, Y., Guo, T., Wang, Z., & Zhao, Y. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb00551k · Cited by 54
NAD+ administration decreases doxorubicin-induced liver damage of mice by enhancing antioxidation capacity and decreasing DNA damage
Wang, B., Ma, Y., Kong, X., et al. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.01.013 · Cited by 52
Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells
Rui, M., Qu, Y., Gao, T., Ge, Y., Feng, C., & Xu, X. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s122171 · Cited by 55
“The anthracycline doxorubicin (Dox) is one of the most efficacious anticancer chemotherapeutics for the treatment of a broad range of neoplasms, such as breast cancer, acute leukemia, and malignant lymphoma.(11) In clinical trials, the”
Background
Attenuation of doxorubicin-induced cardiotoxicity and genotoxicity by an indole-based natural compound 3,3′-diindolylmethane (DIM) through activation of Nrf2/ARE signaling pathways and inhibiting apoptosis
Hajra, S., Basu, A., Roy, S. S., et al. (2017) · Free Radical Research · doi:10.1080/10715762.2017.1381694 · Cited by 52
“Conventionally, it is used to treat some forms of leukemia and Hodgkin’s lymphoma as well as cancers of the bladder, breast, stomach, lung, ovary, thyroid, soft tissue sarcoma, and multiple myelomas [1].”
Role of flavonoids against adriamycin toxicity
Navarro‐Hortal, M. D., Varela‐López, A., Romero‐Márquez, J. M., Rivas‐García, L., Speranza, L., Battino, M. A., & Quiles, J. L. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111820 · Cited by 52
Hybrid polymer micelles capable of cRGD targeting and pH-triggered surface charge conversion for tumor selective accumulation and promoted uptake
Hu, X., Guan, X., Li, J., et al. (2014) · Chemical Communications · doi:10.1039/c4cc04056b · Cited by 51
Therapeutic agent-based infinite coordination polymer nanomedicines for tumor therapy
Zhang, S., Zhang, S., Luo, S., & Wu, D. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214059 · Cited by 51
HDAC6 inhibition reverses long-term doxorubicin-induced cognitive dysfunction by restoring microglia homeostasis and synaptic integrity
McAlpin, B. R., Mahalingam, R., Singh, A. K., Dharmaraj, S., Chrisikos, T. T., Boukelmoune, N., Kavelaars, A., & Heijnen, C. J. (2021) · Theranostics · doi:10.7150/thno.67410 · Cited by 52
“Doxorubicin’s efficacy is associated with systemic inflammation and oxidative stress in the periphery, but its effects on the central nervous system (CNS) that initiate and sustain CICD are relatively unknown [4].”
Background
Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells
Ivanova, L., Zandberga, E., Siliņa, K., Kalniņa, Z., Ābols, A., Endzeliņš, E., Vendina, I., Romanchikova, N., Hegmane, A., Trapencieris, P., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2635-1 · Cited by 50
Chronic Doxorubicin Cardiotoxicity Modulates Cardiac Cytochrome P450-Mediated Arachidonic Acid Metabolism in Rats
Alsaad, A. M. S., Zordoky, B. N. M., El-Sherbeni, A. A., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.046631 · Cited by 51
“However, the clinical situation requires chronic administration of the drug where the total cumulative dose is the only currently used predictor of cardiotoxicity (Swain et al., 2003; Carvalho et al., 2009).”
BackgroundInfluential
Alterations of biomechanics in cancer and normal cells induced by doxorubicin
Frączkowska, K., Bacia, M., Przybyło, M., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.040 · Cited by 51
Aerobic Exercise During Early Murine Doxorubicin Exposure Mitigates Cardiac Toxicity
Wang, F., Iskra, B. S., Kleinerman, E. S., Alvarez‐Florez, C., Andrews, T. C., Shaw, A., Chandra, J., Schadler, K., & Aune, G. J. (2018) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001112 · Cited by 51
Fluorescent and magnetic stellate mesoporous silica for bimodal imaging and magnetic hyperthermia
Perton, F., Tasso, M., Medina, G. A. M., Ménard, M., Blanco-Andujar, C., Portiansky, E. L., van Raap, M. B. F., Bégin, D., Meyer, F., Bégin‐Colin, S., et al. (2019) · Applied Materials Today · doi:10.1016/j.apmt.2019.06.006 · Cited by 51
Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy
Aparicio-Blanco, J., Sanz-Arriazu, L., Lorenzoni, R., & Blanco‐Prieto, M. J. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119283 · Cited by 50
Multi-layered cellulose nanocrystal system for CD44 receptor-positive tumor-targeted anticancer drug delivery
Seo, J., Lee, S. Y., Hwang, C., et al. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.193 · Cited by 51
GFP Plasmid and Chemoreagent Conjugated with Graphene Quantum Dots as a Novel Gene Delivery Platform for Colon Cancer Inhibition In Vitro and In Vivo
Lo, P.-Y., Lee, G.-Y., Zheng, J.-H., Huang, J.-H., Cho, E.-C., & Lee, K.-C. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00631 · Cited by 52
Cancer Therapy-Induced Cardiotoxicity—A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy
Choksey, A., & Timm, K. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010441 · Cited by 76
“It is regularly used to treat solid and haematological malignancies, including breast cancer, ovarian cancer and acute myeloid leukaemia [9].”
Background
Gambogic Acid Sensitizes Ovarian Cancer Cells to Doxorubicin Through ROS-Mediated Apoptosis
Wang, J., & Yuan, Z. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9534-7 · Cited by 50
“vomiting, stomatitis, neurologic disturbances, myocardial toxicity, alopecia, and bone marrow aplasia [6].”
Background
Dual effects of quercetin in doxorubicin‐induced nephrotoxicity in rats and its modulation of the cytotoxic activity of doxorubicin on human carcinoma cells
Heeba, G. H., & Mahmoud, M. E. (2014) · Environmental Toxicology · doi:10.1002/tox.22075 · Cited by 50
“However, its effectiveness has been limited by the occurrence of dose related renal, myocardial and bone marrow toxicities (Carvalho et al., 2009).”
Background
Amphiphilic Polyelectrolyte/Prodrug Nanoparticles Constructed by Synergetic Electrostatic and Hydrophobic Interactions with Cooperative pH-Sensitivity for Controlled Doxorubicin Delivery
Huang, P., Wang, W., Zhou, J., Zhao, F., Zhang, Y., Liu, J., Liu, J., Dong, A., Kong, D., & Zhang, J. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b00962 · Cited by 50
Triphenyl Phosphine-Functionalized Chitosan Nanoparticles Enhanced Antitumor Efficiency Through Targeted Delivery of Doxorubicin to Mitochondria
Hou, J., Yu, X., Shen, Y., et al. (2017) · Nanoscale Research Letters · doi:10.1186/s11671-017-1931-1 · Cited by 50
Enhanced anticancer efficiency of doxorubicin against human glioma by natural borneol through triggering ROS-mediated signal
Cao, W.-Q., Li, Y., Hou, Y., Yang, M., Fu, X., Zhao, B., Jiang, H., & Fu, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109261 · Cited by 52
Involvement of Abnormal Gut Microbiota Composition and Function in Doxorubicin-Induced Cardiotoxicity
Huang, J., Wei, S., Jiang, C., Xiao, Z., Liu, J., Peng, W., Zhang, B., & Li, W. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.808837 · Cited by 50
“However, this anticancer drug also damages other organs like the brain, kidney, and liver (Carvalho et al., 2009).”
Background
High-mobility group box 1-mediated heat shock protein beta 1 expression attenuates mitochondrial dysfunction and apoptosis
Narumi, T., Shishido, T., Otaki, Y., Kadowaki, S., Honda, Y., Funayama, A., Honda, S., Hasegawa, H., Kinoshita, D., Yokoyama, M., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.02.018 · Cited by 50
“Doxorubicin, an anthracycline derivative, is an anticancer drug effective against various types of cancer [1,2].”
Background
Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes
Song, X., Ren, Y., Zhang, J., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.4136 · Cited by 49
Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model
Fernandes, R. S., Silva, J. O., Mussi, S., Lopes, S. C. A., Leite, E. A., Cassali, G., Cardoso, V., Townsend, D. M., Colletti, P., Ferreira, L. A., et al. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1133-3 · Cited by 37
Doxorubicin-loaded pH-sensitive micelles: A promising alternative to enhance antitumor activity and reduce toxicity
Cavalcante, C. H., Fernandes, R. S., Silva, J. D. O., Oda, C. M. R., Leite, E. A., Cassali, G. D., Charlie‐Silva, I., Fernandes, B. H. V., Ferreira, L. A. M., & de Barros, A. L. B. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111076 · Cited by 49
Mannosylated poly(acrylic acid)-coated mesoporous silica nanoparticles for anticancer therapy
Lee, H.-S., Lee, H., Choi, M., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.064 · Cited by 48
Kaempferol attenuates doxorubicin-induced renal tubular injury by inhibiting ROS/ASK1-mediated activation of the MAPK signaling pathway
Wu, Q., Chen, J., Zheng, X., Song, J., Yin, L., Guo, H., Chen, Q., Liu, Y., Ma, Q., Zhang, H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114087 · Cited by 47
Lactobacillus plantarum HY7712 Ameliorates Cyclophosphamide-Induced Immunosuppression in Mice
Jang, S. (2013) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1210.10010 · Cited by 48
“Therefore, reducing the side effects of anticancer drugs such as cyclophosphamide and doxorubicin is necessary [6, 24].”
Background
In vitro and in vivo behavior of DNA tetrahedrons as tumor-targeting nanocarriers for doxorubicin delivery
Kang, J. H., Kim, K., Lee, H., et al. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.06.014 · Cited by 48
Protective effect of proanthocyanidins against doxorubicin‐induced nephrotoxicity in rats
El‐Sayed, E. M., Mansour, A. M., & El-Sawy, W. S. M. (2017) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21965 · Cited by 48
Two purified proteins from royal jelly with in vitro dual anti-hepatic damage potency: Major royal jelly protein 2 and its novel isoform X1
Abu-Serie, M. M., & Habashy, N. H. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.01.210 · Cited by 48
De novo Design of Selective Membrane‐Active Peptides by Enzymatic Control of Their Conformational Bias on the Cell Surface
Shi, J., & Schneider, J. P. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201902470 · Cited by 48
MIL-125-based nanocarrier decorated with Palladium complex for targeted drug delivery
Bagherzadeh, M., Safarkhani, M., Kiani, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16058-w · Cited by 48
Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy
Shim, N., Jeon, S. I., Yang, S., Park, J. Y., Jo, M., Kim, J., Choi, J., Yun, W. S., Kim, J., Lee, Y. J., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121806 · Cited by 49
Ferrocene‐Based Polymeric Nanoparticles Carrying Doxorubicin for Oncotherapeutic Combination of Chemotherapy and Ferroptosis
Lin, J., Yang, H., Zhang, Y., et al. (2022) · Small · doi:10.1002/smll.202205024 · Cited by 47
Chemotherapeutic drugs for soft tissue sarcomas: a review
Tian, Z., & Yao, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1199292 · Cited by 48
“In addition, doxorubicin aids in the immune-mediated clearance of tumor cells (Carvalho et al., 2009; Sritharan and Sivalingam, 2021).”
Background
Charge-Switchable nanoparticles to enhance tumor penetration and accumulation
Souri, M., Golzaryan, A., & Soltani, M. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114310 · Cited by 47
Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury
Avagimyan, A. A., Pogosova, N. V., Kakturskiy, L., et al. (2024) · Cardiovascular Pathology · doi:10.1016/j.carpath.2024.107683 · Cited by 47
Interleukin 24: Mechanisms and therapeutic potential of an anti-cancer gene
Whitaker, E. L., Filippov, V. A., & Duerksen-Hughes, P. J. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.08.004 · Cited by 47
A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts
He, H., Liu, C., Wu, Y., et al. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2456-8 · Cited by 47
Apoptosis oxidative damage‐mediated and antiproliferative effect of selenylated imidazo[1,2‐a]pyridines on hepatocellular carcinoma HepG2 cells and in vivo
dos Santos, D. C., Rafique, J., Saba, S., Almeida, G. M., Siminski, T., da Silva, C. D. P., Filho, D. W., Zamoner, A., Braga, A. L., Pedrosa, R. C., et al. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22663 · Cited by 46
Therapeutic potential of thymoquinone in combination therapy against cancer and cancer stem cells
Fatfat, Z., Fatfat, M., & Gali‐Muhtasib, H. U. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i7.522 · Cited by 46
Composite Nanoarchitectonics of Magnetic Silicon Dioxide-Modified Chitosan for Doxorubicin Delivery and In Vitro Cytotoxicity Assay
Nassar, M. Y., El-Salhy, H. I., El-Shiwiniy, W. H., Abdelaziz, G., & El-Shiekh, R. (2022) · Journal of Inorganic and Organometallic Polymers and Materials · doi:10.1007/s10904-022-02498-4 · Cited by 47
“Despite its efficacy and success in treating different kinds of tumors, there are several side effects associated with its use that limit its function such as nausea and vomiting, stomatitis, baldness, gastrointestinal disturbances, neurologic disturbances, bone marrow aplasia, and cumulative cardiotoxicity [21], as w…”
Background
Novel thiosemicarbazone and thiazolidin‐4‐one derivatives containing vanillin core: Synthesis, characterization, and anticancer activity studies
Tokalı, F. S., Şenol, H., Katmerlikaya, T. G., Dağ, A., & Şendil, K. (2023) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4619 · Cited by 46
Therapeutic Targeting of DNA Replication Stress in Cancer
Gu, L., Hickey, R. J., & Malkas, L. H. (2023) · Genes · doi:10.3390/genes14071346 · Cited by 52
Role of RIPK3‑CaMKII‑mPTP signaling pathway‑mediated necroptosis in cardiovascular diseases (Review)
Chen, S., Guan, S., Yan, Z., Ouyang, F., Li, S., Liu, L., & Zhong, J. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5301 · Cited by 46
“dOX is a first‐line chemotherapy drug that is widely used to treat a variety of cancer types, including carcinomas, sarcomas and hematological cancers (120) It causes irrevers‐ ible cardiotoxicity in 30‐40% of patients, resulting in the loss of numerous myocardial cells and ultimately leading to cardiomyopathy and HF,…”
Background
Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches
Lyrio, R. M. D. C., Rocha, B. R. A., Corrêa, A. L. R. M., Mascarenhas, M. G. S., Santos, F. L., MAIA, R. D. H., Segundo, L. B., de Almeida, P. A. A., Moreira, C. M. O., & Sassi, R. H. (2024) · Frontiers in Nephrology · doi:10.3389/fneph.2024.1436896 · Cited by 48
Physical exercise mitigates doxorubicin-induced brain cortex and cerebellum mitochondrial alterations and cellular quality control signaling
Marques‐Aleixo, I., Alves, E. S., Balça, M. M., Moreira, P. I., Oliveira, P. J., Magalhães, J., & Ascensão, A. A. M. R. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.12.002 · Cited by 47
Self-citation
Glucose and Triphenylphosphonium Co-Modified Redox-Sensitive Liposomes to Synergistically Treat Glioma with Doxorubicin and Lonidamine
Peng, Y., Lu, J., Li, R., Zhao, Y., Hai, L., Guo, L., & Wu, Y. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c02404 · Cited by 48
Phosphocreatine attenuates doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and activating TAK1 to promote myocardial survival in vivo and in vitro
Wang, C., Hu, L., Guo, S., et al. (2021) · Toxicology · doi:10.1016/j.tox.2021.152881 · Cited by 45
Role of chemotherapeutic drugs in immunomodulation of cancer
Mukherjee, O., Rakshit, S., Shanmugam, G., & Sarkar, K. (2023) · Current Research in Immunology · doi:10.1016/j.crimmu.2023.100068 · Cited by 47
Protective effects of berberine against doxorubicin-induced cardiotoxicity in rats by inhibiting metabolism of doxorubicin
Hao, G., Yu, Y., Gu, B., et al. (2015) · Xenobiotica · doi:10.3109/00498254.2015.1034223 · Cited by 45
“…treatment of cancer since 1970, is a broad-spectrum anthracycline antibiotic widely used to treat various types of human neoplastic disease, including lymphoblastic, hematopoietic and a wide range of solid tumors, such as lung, breast and thyroid cancer (Blanco et al., 2008; Carvalho et al., 2009).”
Background
Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways
Barış, V. Ö., Dinçsoy, A. B., Gedikli, E., Zırh, S., Muftuoglu, S. F., & Erdem, A. (2021) · Cardiovascular Toxicology · doi:10.1007/s12012-021-09665-y · Cited by 45
Quercetin Alleviates the Immunotoxic Impact Mediated by Oxidative Stress and Inflammation Induced by Doxorubicin Exposure in Rats
Farag, M. R., Moselhy, A. A. A., El‐Mleeh, A., Aljuaydi, S. H., Ismail, T. A., Cerbo, A. D., Crescenzo, G., & Abou‐Zeid, S. M. (2021) · Antioxidants · doi:10.3390/antiox10121906 · Cited by 45
Chemotherapeutic drugs induce oxidative stress associated with DNA repair and metabolism modulation
Zhang, Y., Ding, C., Zhu, W., Li, X., Chen, T., Liu, Q., Zhou, S., Zhang, T., & Ma, W. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120242 · Cited by 48
tRNA Binding to Antitumor Drug Doxorubicin and Its Analogue
Agudelo, D., Bourassa, P., Beauregard, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069248 · Cited by 44
“1) are extensively used as chemotherapeutic agents for the treatment of several types of cancers including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers [1].”
Background
Covalently Linking Poly(lactic‐co‐glycolic acid) Nanoparticles to Microbubbles Before Intravenous Injection Improves their Ultrasound‐Targeted Delivery to Skeletal Muscle
Burke, C. W., Hsiang, Y.-H. J., Alexander, E., et al. (2011) · Small · doi:10.1002/smll.201001934 · Cited by 44
α-Enolase plays a catalytically independent role in doxorubicin-induced cardiomyocyte apoptosis and mitochondrial dysfunction
Gao, S., Li, H., Feng, X., Li, M., Liu, Z., Cai, Y., Lü, J., Huang, X., Wang, J., Li, Q., et al. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.11.007 · Cited by 45
“Dox is a well-known inducer of cardiomyocyte apoptosis [1].”
Background
Molecularly imprinted fluorescent probe based on FRET for selective and sensitive detection of doxorubicin
Xu, Z., Deng, P., Li, J., Xu, L., & Tang, S. (2017) · Materials Science and Engineering B · doi:10.1016/j.mseb.2017.02.005 · Cited by 46
Supramolecular Modular Approach toward Conveniently Constructing and Multifunctioning a pH/Redox Dual-Responsive Drug Delivery Nanoplatform for Improved Cancer Chemotherapy
Liu, J., Liu, X., Yuan, Y., Li, Q., Chang, B., Xu, L., Cai, B., Qi, C., Li, C., Jiang, X., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b05232 · Cited by 44
Doxorubicin-loaded Fe 3 O 4 -ZIF-8 nano-composites for hepatocellular carcinoma therapy
Cheng, C., Li, C., Zhu, X., Han, W., Li, J., & Lv, Y. (2019) · Journal of Biomaterials Applications · doi:10.1177/0885328219836540 · Cited by 43
Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS
Schöffski, P., Lahmar, M. M., Lucarelli, A., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-1291 · Cited by 44
Berberine Attenuates Doxorubicin-Induced Cardiotoxicity in Mice
Zhao, X., Zhang, J., Tong, N., Liao, X., Wang, E., Li, Z., Luo, Y., & Zuo, H. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900514 · Cited by 44
Cisplatin-based combination therapy for cancer
Minerva, Bhat, A., Verma, S., Chander, G., Jamwal, R. S., Sharma, B., Bhat, A., Katyal, T., Kumar, R., & Shah, R. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_792_22 · Cited by 44
Advances in Doxorubicin Chemotherapy: Emerging Polymeric Nanocarriers for Drug Loading and Delivery
Bhadran, A., Polara, H., Babanyinah, G. K., Baburaj, S., & Stefan, M. C. (2025) · Cancers · doi:10.3390/cancers17142303 · Cited by 58
“A significant concern with DOX therapy is its systemic toxicity, particularly its cardiotoxic effects, which can lead to acute and chronic heart complications, including cardiomyopathy and heart failure [6].”

Authors: Carvalho, C., Santos, R., Cardoso, S., Correia, S., Oliveira, P., Santos, M., & Moreira, P.
Affiliations: Centro de Neurociências e Biologia Celular (PT)
Corresponding author: Moreira, Paula
ORCID: Carvalho, Cristina
Santos, Renato
Cardoso, Susana
Oliveira, Paulo
Santos, Maria
Moreira, Paula
Venue: Current Medicinal Chemistry
Publisher: Bentham Science Publishers Ltd.
Published: 2009-09-01
Volume: 16
Issue: 25
Pages: 3267-3285
ISSN: 0929-8673 (ISSN-L)
DOI: 10.2174/092986709788803312
OpenAlex: W2102897174
Cited by: 1,509
References: 0
Citations by year: 2026: 102 · 2025: 147 · 2024: 174 · 2023: 169 · 2022: 153 · 2021: 150 · 2020: 120 · 2019: 85 · 2018: 84 · 2017: 53 · 2016: 63 · 2015: 62 · 2014: 43 · 2013: 35 · 2012: 29
FWCI: 14.12
Type: journal article
Language: en
Open access: closed
Locations: Current Medicinal Chemistry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords: doxorubicin, anthracyclines, cardiotoxicity, drug toxicity mechanisms, anticancer mechanism, neurotoxicity, nephrotoxicity, hepatotoxicity, chemotherapy side effects
MeSH terms: Antibiotics, Antineoplastic, Doxorubicin, Humans, Molecular Conformation, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Doxorubicin: The Good, the Bad and the Ugly Effect

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks